MeiraGTx

MeiraGTx

Biotechnology
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

$826.8M

Market Cap • 11/17/2026

2018

(8 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

3,8

P/S

2,1

P/EBITDA

4,3

P/OCF

610,2

P/FCF

—

P/E

9,7

BVPS

2,2

EPS

0,9

Market Cap

Market Cap

826,8M

EV

776,1M

EV/Revenue

1,9

EV/EBITDA

4

EV/EBIT

4,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-18,6%

Total Yield

-18,6%

Payout

0%

Retained Earnings

-753M

Profitability

Gross Margin

99,5%

EBITDA Margin

47,8%

EBIT Margin

44,8%

Net Margin

19,4%

D&A/EBITDA

0%

R&D/Revenue

39,8%

Capex/Revenue

1,1%

Capex/D&A

36,8%

Capex/OCF

320,6%

SBC/OCF

1527,5%

% PPE

31,5%

% Goodwill

0%

ROE

89,5%

ROIC

88,1%

Growth

CAGR Revenue 5Y

81,4%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

4,6

Quick Ratio

3,9

Interest Coverage

2317,1%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium